Company Profile

Medeia is engaged in the generation and further development of biomedical inventions. We have several programs in our R&D pipeline with the ultimate goal to treat devastating degenerative human diseases. The core therapeutic areas include diseases of the central nervous system (CNS) such as Alzheimer’s disease and Amyotrophic lateral sclerosis.

Medeia conducts high quality, but cost-effective discovery and early development of drug candidates and autologous cell based treatments. Medeia is committed to seeking partnerships with global pharmaceutical and biotech companies to advance our products further to clinical trials and eventually to the market. We also seek collaborators with cutting edge technologies or early stage compounds to complement our objectives.

Medeia’s track record in commercializing innovative therapeutic principles is convincing. We have entered into a research and option-based agreement with a leading pharmaceutical company to advance new chemical entities (NCEs) hitting a novel target discovered by Medeia into clinical trials.